PodParley PodParley
PodParley
MPR Weekly Dose #65 - Johnson & Johnson's vaccine candidate; Blood donations during pandemic; New Tx for heart failure with reduced ejection fraction; A potential Alzheimer drug; Changes to vinca alkaloid labeling episode artwork

EPISODE · Jan 22, 2021 · 10 MIN

MPR Weekly Dose #65 - Johnson & Johnson's vaccine candidate; Blood donations during pandemic; New Tx for heart failure with reduced ejection fraction; A potential Alzheimer drug; Changes to vinca alkaloid labeling

from MPR Weekly Dose

On this week's MPR pod we take a look at the current status of Johnson & Johnson's COVID-19 vaccine candidate; Considerations in assessing blood donors during the pandemic; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.

Episode metadata supplied by the publisher feed · Published Jan 22, 2021

Embed this episode

Ready to play

MPR Weekly Dose #65 - Johnson & Johnson's vaccine candidate; Blood donations during pandemic; New Tx for heart failure with reduced ejection fraction; A potential Alzheimer drug; Changes to vinca alkaloid labeling

0:00 10:39

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 10 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on January 22, 2021.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!